{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:45:26Z","timestamp":1793677526857,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The use of antibiotics in mild to severe acute exacerbations of chronic obstructive pulmonary disease (COPD) remains controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To explore in-hospital antibiotic use in severe acute exacerbations of COPD (AECOPD), to analyze determinants of in-hospital antibiotic use, and to investigate its association with hospital length of stay (LOS) and in-hospital mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, observational study was conducted in Ghent University Hospital. Severe AECOPD were defined as hospitalizations for AECOPD (ICD-10 J44.0 and J44.1) discharged between 2016 and 2021. Patients with a concomitant diagnosis of pneumonia or \u2018pure\u2019 asthma were excluded. An alluvial plot was used to describe antibiotic treatment patterns. Logistic regression analyses identified determinants of in-hospital antibiotic use. Cox proportional hazards regression analyses were used to compare time to discharge alive and time to in-hospital death between antibiotic-treated and non-antibiotic-treated AECOPD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 431 AECOPD patients (mean age 70\u00a0years, 63% males) were included. More than two-thirds (68%) of patients were treated with antibiotics, mainly amoxicillin-clavulanic acid. In multivariable analysis, several patient-related variables (age, body mass index (BMI), cancer), treatment-related variables (maintenance azithromycin, theophylline), clinical variables (sputum volume and body temperature) and laboratory results (C-reactive protein (CRP) levels) were associated with in-hospital antibiotic use independent of sputum purulence, neutrophil counts, inhaled corticosteroids and intensive care unit of which CRP level was the strongest determinant. The median hospital LOS was significantly longer in antibiotic-treated patients (6\u00a0days [4\u201310]) compared to non-antibiotic-treated patients (4\u00a0days [2\u20137]) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, Log rank test). This was indicated by a reduced probability of hospital discharge even after adjustment for age, sputum purulence, BMI, in-hospital systemic corticosteroid use and forced expiratory volume in one second (FEV<jats:sub>1<\/jats:sub>) (adjusted hazard ratio 0.60; 95% CI 0.43; 0.84). In-hospital antibiotic use was not significantly associated with in-hospital mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this observational study in a Belgian tertiary hospital, in-hospital antibiotic use among patients with severe AECOPD was determined by the symptom severity of the exacerbation and the underlying COPD severity as recommended by the guidelines, but also by patient-related variables. Moreover, in-hospital antibiotic use was associated with a\u00a0longer hospital stay, which may be linked to their disease severity, slower response to treatment\u00a0or 'harm' due to antibiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Number: B670201939030; date of registration: March 5, 2019.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02426-3","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:02:32Z","timestamp":1682409752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In-hospital antibiotic use for severe chronic obstructive pulmonary disease exacerbations: a retrospective observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna","family":"Vanoverschelde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00eb","family":"Van Hoey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franky","family":"Buyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Den Blauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Van Braeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lies","family":"Lahousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2426_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2022 Report 2022 Available from: https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/12\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf."},{"issue":"9589","key":"2426_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","volume":"370","author":"JA Wedzicha","year":"2007","unstructured":"Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet (London, England). 2007;370(9589):786\u201396.","journal-title":"Lancet (London, England)"},{"issue":"22","key":"2426_CR3","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMra0800353","volume":"359","author":"S Sethi","year":"2008","unstructured":"Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"2426_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s15010-019-01350-1","volume":"48","author":"M Moghoofei","year":"2020","unstructured":"Moghoofei M, AzimzadehJamalkandi S, Moein M, Salimian J, Ahmadi A. Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Infection. 2020;48(1):19\u201335.","journal-title":"Infection"},{"issue":"6","key":"2426_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jinf.2013.08.010","volume":"67","author":"R Wilson","year":"2013","unstructured":"Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013;67(6):497\u2013515.","journal-title":"J Infect"},{"key":"2426_CR6","first-page":"CD010257","volume":"10","author":"DJ Vollenweider","year":"2018","unstructured":"Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10:CD010257.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2426_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/ijms18071344","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Anzueto A. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18(7):1344.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2426_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","volume":"106","author":"NR Anthonisen","year":"1987","unstructured":"Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196\u2013204.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2426_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/15412555.2020.1766433","volume":"17","author":"K Chen","year":"2020","unstructured":"Chen K, Pleasants KA, Pleasants RA, Beiko T, Washburn RG, Yu Z, et al. A systematic review and meta-analysis of sputum purulence to predict bacterial infection in COPD exacerbations. COPD. 2020;17(3):311\u20137.","journal-title":"COPD"},{"key":"2426_CR10","unstructured":"The Belgian Society for Infectiology and Clinical Microbiology. Acute infectious exacerbation of bronchitis and tracheobronchitis in (adolescents) and adults with COPD 2019. Available from: https:\/\/www.bvikm.org\/documenten."},{"issue":"1","key":"2426_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12890-022-01958-4","volume":"22","author":"G Hoult","year":"2022","unstructured":"Hoult G, Gillespie D, Wilkinson TMA, Thomas M, Francis NA. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. BMC Pulm Med. 2022;22(1):194.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"2426_CR12","doi-asserted-by":"publisher","first-page":"1802014","DOI":"10.1183\/13993003.02014-2018","volume":"53","author":"HJ Prins","year":"2019","unstructured":"Prins HJ, Duijkers R, van der Valk P, Schoorl M, Daniels JMA, van der Werf TS, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019;53(5):1802014.","journal-title":"Eur Respir J"},{"key":"2426_CR13","unstructured":"Belgian Antibiotic Policy Coordination Commission. Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. 2021. Available from: https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/belgische_gids_bapcoc_nl_2021_a4_2.pdf."},{"issue":"3","key":"2426_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1753465812472387","volume":"7","author":"C Llor","year":"2013","unstructured":"Llor C, Bjerrum L, Munck A, Hansen MP, Cordoba GC, Strandberg EL, et al. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice. Ther Adv Respir Dis. 2013;7(3):131\u20137.","journal-title":"Ther Adv Respir Dis"},{"issue":"705","key":"2426_CR15","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.3399\/BJGP.2020.0823","volume":"71","author":"D Gillespie","year":"2021","unstructured":"Gillespie D, Butler CC, Bates J, Hood K, Melbye H, Phillips R, et al. Associations with antibiotic prescribing for acute exacerbation of COPD in primary care: secondary analysis of a randomised controlled trial. Br J Gen Pract. 2021;71(705):e266\u201372.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"2426_CR16","doi-asserted-by":"publisher","first-page":"e0124374","DOI":"10.1371\/journal.pone.0124374","volume":"10","author":"JL Lopez-Campos","year":"2015","unstructured":"Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. European CAt. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLoS One. 2015;10(4):e0124374.","journal-title":"PLoS One."},{"issue":"1","key":"2426_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1378\/chest.12-0649","volume":"143","author":"MS Stefan","year":"2013","unstructured":"Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest. 2013;143(1):82\u201390.","journal-title":"Chest"},{"issue":"2","key":"2426_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1060028018799696","volume":"53","author":"SE Petite","year":"2019","unstructured":"Petite SE, Murphy JA. Systemic corticosteroid and antibiotic use in hospitalized patients with chronic obstructive pulmonary disease exacerbation. Ann Pharmacother. 2019;53(2):144\u201350.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"2426_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1017\/ice.2017.94","volume":"38","author":"JS Gerber","year":"2017","unstructured":"Gerber JS, Hersh AL, Kronman MP, Newland JG, Ross RK, Metjian TA. Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals. Infect Control Hosp Epidemiol. 2017;38(8):993\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2426_CR20","unstructured":"Klinische Biologie UZ gent. UZ Gent laboratoriumgids [03\/08\/2022]. Available from: http:\/\/labgids.gent\/."},{"issue":"1","key":"2426_CR21","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1136\/bmjresp-2019-000535","volume":"7","author":"Y Wang","year":"2020","unstructured":"Wang Y, Bos JH, Boezen HM, Alffenaar JC, van Boven JFM, Schuiling-Veninga CCM, et al. Influence of age on real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study. BMJ Open Respir Res. 2020;7(1):e000535.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"2426_CR22","doi-asserted-by":"publisher","first-page":"00034","DOI":"10.1183\/23120541.00034-2015","volume":"2","author":"M Ruparel","year":"2016","unstructured":"Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. ERJ Open Res. 2016;2(1):00034\u20132015.","journal-title":"ERJ Open Res"},{"issue":"2","key":"2426_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1513\/AnnalsATS.201208-043OC","volume":"10","author":"A Singanayagam","year":"2013","unstructured":"Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"2426_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1183\/09031936.00021812","volume":"41","author":"JL Lopez-Campos","year":"2013","unstructured":"Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. European CAt. European COPD Audit: design, organisation of work and methodology. Eur Respir J. 2013;41(2):270\u20136.","journal-title":"Eur Respir J"},{"issue":"suppl_6","key":"2426_CR25","doi-asserted-by":"publisher","first-page":"vi59","DOI":"10.1093\/jac\/dky119","volume":"73","author":"A Versporten","year":"2018","unstructured":"Versporten A, Gyssens IC, Pulcini C, Monnier AA, Schouten J, Milanic R, et al. Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. J Antimicrob Chemother. 2018;73(suppl_6):vi59\u201366.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2426_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/BF03256673","volume":"2","author":"D Lieberman","year":"2003","unstructured":"Lieberman D, Lieberman D. Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med. 2003;2(6):459\u201368.","journal-title":"Am J Respir Med"},{"key":"2426_CR27","volume":"358","author":"TB Drug","year":"2017","unstructured":"Drug TB. Penicillin allergy-getting the label right. BMJ. 2017;358: j3402.","journal-title":"BMJ"},{"issue":"12","key":"2426_CR28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","volume":"203","author":"Z Wang","year":"2021","unstructured":"Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis. Am J Respir Crit Care Med. 2021;203(12):1488\u2013502.","journal-title":"Am J Respir Crit Care Med"},{"key":"2426_CR29","unstructured":"the Dutch Association of Physicians in Chest Medicine and Tuberculosis (NVALT). Diagnostiek en behandeling COPD-longaanval in het ziekenhuis, 2017. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/behandeling_copd-longaanval_in_het_ziekenhuis\/antibiotica_bij_copd.html."},{"issue":"8","key":"2426_CR30","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1440-1843.2009.01615.x","volume":"14","author":"AM Tsimogianni","year":"2009","unstructured":"Tsimogianni AM, Papiris SA, Kanavaki S, Stathopoulos GT, Sotiropoulou C, Manali ED, et al. Predictors of positive sputum cultures in exacerbations of chronic obstructive pulmonary disease. Respirology (Carlton, Vic). 2009;14(8):1114\u201320.","journal-title":"Respirology (Carlton, Vic)"},{"issue":"9298","key":"2426_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(01)07097-0","volume":"358","author":"S Nouira","year":"2001","unstructured":"Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet (London, England). 2001;358(9298):2020\u20135.","journal-title":"Lancet (London, England)"},{"key":"2426_CR32","unstructured":"Lapeere H. Penicilline allergie 2019. Available from: https:\/\/www.uzgent.be\/nl\/home\/Lists\/PDFs%20zorgaanbod\/Apotheek_Allergie%20en%20antibiotica.pdf."},{"issue":"8","key":"2426_CR33","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/all.14292","volume":"75","author":"AL Van Gasse","year":"2020","unstructured":"Van Gasse AL, Oulkadi R, Mousati Z, Ebo DG, Chiriac AM, Van Der Poorten MM, et al. Prevalence of self-reported and confirmed penicillin allergy in a Belgian outpatient population. Allergy. 2020;75(8):2111\u20135.","journal-title":"Allergy"},{"key":"2426_CR34","doi-asserted-by":"crossref","unstructured":"Vermeersch K, Gabrovska M, Aumann J, Demedts IK, Corhay JL, Marchand E, et al. Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2019; 200(7):857\u201368.","DOI":"10.1164\/rccm.201901-0094OC"},{"key":"2426_CR35","doi-asserted-by":"crossref","unstructured":"Baalbaki N, Giuliano C, Hartner CL, Kale-Pradhan P, Johnson L. Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD. J Gen Intern Med. 2022;37(16):4183\u20138.","DOI":"10.1007\/s11606-022-07486-5"},{"key":"2426_CR36","first-page":"2257","volume":"10","author":"MY Dai","year":"2015","unstructured":"Dai MY, Qiao JP, Xu YH, Fei GH. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD assessment test. Int J Chron Obstruct Pulmon Dis. 2015;10:2257\u201363.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"2426_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","volume":"150","author":"M Bafadhel","year":"2016","unstructured":"Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150(2):320\u20138.","journal-title":"Chest"},{"issue":"6","key":"2426_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/15412555.2020.1841745","volume":"17","author":"C Echevarria","year":"2020","unstructured":"Echevarria C, Steer J, Bourke SC. Coding of COPD Exacerbations and the Implications on Clinical Practice, Audit and Research. COPD. 2020;17(6):706\u201310.","journal-title":"COPD"},{"key":"2426_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2466-15-5","volume":"15","author":"GG Rohde","year":"2015","unstructured":"Rohde GG, Koch A, Welte T, group As. Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD\u2013the ABACOPD study. BMC Pulm Med. 2015;15:5.","journal-title":"BMC Pulm Med."},{"issue":"suppl 66","key":"2426_CR40","first-page":"1727","volume":"60","author":"GG Rohde","year":"2022","unstructured":"Rohde GG, H\u00e4ckl S, Koch A, Kolditz M, Timmermann H, Andreas S, et al. Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD - Results from the ABACOPD study. Eur Respir J. 2022;60(suppl 66):1727.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02426-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02426-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02426-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:03:06Z","timestamp":1682409786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02426-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02426-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been performed in accordance with the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of Ghent University Hospital (B670201939030) and, due to its retrospective nature, informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.V.B. is co-author of the Belgian outpatient and inpatient guidelines for AECOPD. L.L. reports honoraria for a lecture from the Institute for Continuing Study of Pharmacists (IPSA) and a fee for external expert consultation from AstraZeneca, outside the submitted work. A.V. reports a honorarium for a lecture from the Flemish Association of Hospital Pharmacists (VZA), outside the submitted work. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}